Alnylam Pharmaceuticals is Monday's IBD Stock Of The Day, with Alnylam stock flashing a buy signal as analysts expect strong quarterly sales for the biomed's product that is taking on Pfizer and BridgeBio Pharma.
Alnylam develops RNA interference therapeutics for genetic, cardiovascular, metabolic and neurological diseases. RNA interference (RNAi) is a process inside your body that regulates how genes make new proteins. Proteins can sometimes cause or contribute to disease.
In March, the biotech play won a second Food and Drug Administration approval for its drug Amvuttra.
Amvuttra was already approved to treat patients with transthyretin amyloid polyneuropathy, a rare disease in which abnormal protein builds up on the nerves, causing systemic damage. However, the FDA signed off in March on it in patients with cardiomyopathy, a significantly bigger market.
Amvuttra now takes on Pfizer's Vyndaqel and BridgeBio's Attruby. However, while Vyndaqel and Attruby are daily pills, Amvuttra is a shot given every six months.
Morgan Stanley analyst Michael Ulz on Oct. 6 raised his ALNY price target to 475 from 405 amid expectations of "Amvuttra launch momentum" with "robust" third-quarter Amvuttra sales.
The biotech company is expected to report third-quarter earnings on Oct. 23. Analyst consensus has quarterly earnings per share growing to 46 cents, up from a 86 cent per share loss a year ago, according to FactSet. However, the Sharp consensus, which tracks recent analyst revision trends for a potentially more accurate estimate, predicts EPS of 71 cents in Q3 2025.
Analysts see revenue increasing 86% to $932 million, according to FactSet. Consensus has Amvuttra sales totaling $575 million, but Morgan Stanley sees revenue coming in at $650 million to $680 million.
"We expect launch momentum to continue and see opportunity for another beat and raise," Ulz wrote.
Investors can keep tabs on leading stocks with Leaderboard, the IBD 50 list of top growth stocks and IBD SwingTrader along with the elite IBD Sector Leaders list.
Alnylam Stock Performance
Shares of Alnylam advanced 2.3% to 470.80 in Monday's stock market, crossing a downward-sloping trendline in an emerging flat base, according to MarketSurge charts.
If Alnylam stock remains below the consolidation's left side for the remainder off the week, it would complete a flat base pattern. The base would present a traditional buy point of 484.21. Last week, Alnylam stock gained nearly 1% to 460.46, finding support at the 10-week moving average.
Shares have held near the 21-day exponential moving average for weeks.
Aggressive investors could look for early entries from the downward-sloping trendline, or use a move above the short-term high of 467.42.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
While Morgan Stanley sounded a bullish tone earlier this month, JPMorgan on Monday maintained an overweight rating on Alnylam stock and reduced its price target by two dollars to 473.
Meanwhile, Stifel analyst Paul Matteis (also on Oct. 6) raised the firm's price target on Alnylam to 495 from 441. Overall, ALNY has an average overweight rating and a price target of 473.96, according to FactSet.
The 673 stocks in the crowded IBD-tracked Medical-Biomed/Biotech industry group have collectively advanced around 15% in the 2025 stock market. That's good for the seventh-best industry group out of the 197 tracked by IBD. ALNY shares have gained around 100% in this year's stock market.
Alnylam stock has an 82 Composite Rating out of a best-possible 99. The stock also has a robust 94 Relative Strength Rating along with a poor 27 EPS Rating.
Please follow Kit Norton on X @KitNorton for more coverage.
YOU MAY ALSO LIKE:
Get Full Access To IBD Stock Lists And Ratings
Why This IBD Tool Simplifies The Search For Top Stocks
IBD Digital: Unlock IBD's Premium Lists, Tools And Analysis Today
How To Invest: Rules For When To Buy And Sell In Bull And Bear Markets
